Patents by Inventor David M. Valenzuela

David M. Valenzuela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Dmk receptor
    Patent number: 5656473
    Abstract: The present invention provides for a gene, designated as dmk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the dmk gene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between Dmk and agents that initiate signal transduction through binding to Dmk.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: August 12, 1997
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Eduardo A. Rojas
  • Monoclonal antibodies recognizing parathyroid hormone-like protein
    Patent number: 5217896
    Abstract: This invention provides a monoclonal antibody which specifically forms a complex with amino acids 1-87 of PTHLP which does not form a complex with amino acids 1-34 of PTHLP, and which forms a complex with the epitope to which any of the monoclonal antibodies produced by the hybridomas 212-10.7, (ATCC Accession No. HB9930), 199-999 (ATCC Accession No. HB9929), 199-278 (ATCC Accession No. HB9931), is directed.This invention further provides methods of detecting PTHLP and of diagnosing and treating humoral hypercalcemia of malignancy.
    Type: Grant
    Filed: December 30, 1988
    Date of Patent: June 8, 1993
    Assignee: Oncogene Science, Inc.
    Inventors: Steven P. Kramer, David M. Valenzuela, Frederick H. Reynolds, Jr., John M. Sorvillo
  • Monoclonal antibodies directed to epitopes of human transforming growth factor--.alpha. and uses thereof
    Patent number: 5190858
    Abstract: The present invention provides a monoclonal antibody which specifically forms a complex with TGF.alpha. in formalin-fixed, paraffin-embedded tissue sections which has an affinity of a least 10.sup.7, and which is directed to the epitope to which monoclonal antibody 213-4.4 (ATCC No. HB9992) is directed. The invention further provides the above-described monoclonal antibody wherein the epitope consists essentially of amino acids 34-43 of TGF.alpha..Additionally, the invention concerns the monoclonal antibody 213-4.4 (ATCC No. HB9992).The invention also provides a method of detecting TGF.alpha. in tissue sections of a tissue in which normal tissue is characterized by the absence of TGF.alpha. and neoplastic tissue is characterized by the presence of TGF.alpha. in a subset of such neoplastic tissue which comprises contacting the tissue sections with an antibody directed to an epitope on TGF.alpha.
    Type: Grant
    Filed: February 1, 1989
    Date of Patent: March 2, 1993
    Assignee: Oncogene Science, Inc.
    Inventors: John M. Sorvillo, David M. Valenzuela, Frederick H. Reynolds, Jr.